<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309618</url>
  </required_header>
  <id_info>
    <org_study_id>AGE-MI</org_study_id>
    <nct_id>NCT03309618</nct_id>
  </id_info>
  <brief_title>Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan</brief_title>
  <official_title>Improving Arterial Wall Characteristics in Patients After Myocardial Infarction With a Very Low Dose of Fluvastatin and Valsartan: Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <brief_summary>
    <textblock>
      The concept of improving arterial wall characteristics by treatment with a very low-dose
      combination of fluvastatin and valsartan (low-flu/val) in stable, post-myocardial infarction
      (MI) patients was tested. The parameters of endothelial function (flow mediated dilatation
      (FMD), reactive hyperemia index) and arterial stiffness (carotid-femoral pulse wave velocity
      (cf-PWV), local carotid PWV and β-stiffness coefficient) were measured before and after 30
      days of treatment, and the residual effect was assessed 10 weeks later. So the investigators
      explored whether low-flu/val added &quot;on-top-of&quot; optimal therapy could improve endothelial
      function and arterial stiffness in post-MI patients. Since these improved parameters are
      well-known predictors of future coronary events, such treatment could decrease cardiovascular
      risk.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brachial flow mediated dilatation (FMD)</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonographically measured flow mediated dilatation of brachial artery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>carotid pulse wave velocity (c-PWV)</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonographically measured pulse wave velocity of carotid artery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>β-stiffness coefficient</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonographically measured β-stiffness coefficient of carotid artery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>carotid-femoral pulse wave velocity (cf-PWV)</measure>
    <time_frame>30 days</time_frame>
    <description>carotid-femoral pulse wave velocity measured by Sphygmocor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reactive hyperemia index (RHI)</measure>
    <time_frame>30 days</time_frame>
    <description>reactive hyperemia index measured by an Endopat device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>brachial flow mediated dilatation (FMD)</measure>
    <time_frame>10 weeks after termination of intervention</time_frame>
    <description>ultrasonographically measured flow mediated dilatation of brachial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid pulse wave velocity (c-PWV)</measure>
    <time_frame>10 weeks after termination of intervention</time_frame>
    <description>ultrasonographically measured pulse wave velocity of carotid artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β-stiffness coefficient</measure>
    <time_frame>10 weeks after termination of intervention</time_frame>
    <description>ultrasonographically measured β-stiffness coefficient of carotid artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid-femoral pulse wave velocity (cf-PWV)</measure>
    <time_frame>10 weeks after termination of intervention</time_frame>
    <description>carotid-femoral pulse wave velocity measured by Sphygmocor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reactive hyperemia index (RHI)</measure>
    <time_frame>10 weeks after termination of intervention</time_frame>
    <description>reactive hyperemia index measured by an Endopat device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 participants received placebo per orally once daily for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)</intervention_name>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of MI in the last 0.5 to 5 years

          -  males

          -  aged under 55 years

        Exclusion Criteria:

          -  diabetes mellitus

          -  manifest peripheral artery disease or carotid artery disease

          -  acute infection

          -  chronic diseases

          -  present therapy with fluvastatin and/or valsartan.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Department of Vascular Diseases, University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>SI-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Neunteufl T, Heher S, Katzenschlager R, Wölfl G, Kostner K, Maurer G, Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol. 2000 Jul 15;86(2):207-10.</citation>
    <PMID>10913483</PMID>
  </reference>
  <reference>
    <citation>Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):168-75. Review.</citation>
    <PMID>12588755</PMID>
  </reference>
  <reference>
    <citation>Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi: 10.1016/j.jacc.2009.10.061. Review.</citation>
    <PMID>20338492</PMID>
  </reference>
  <reference>
    <citation>Stefanadis C, Dernellis J, Tsiamis E, Stratos C, Diamantopoulos L, Michaelides A, Toutouzas P. Aortic stiffness as a risk factor for recurrent acute coronary events in patients with ischaemic heart disease. Eur Heart J. 2000 Mar;21(5):390-6.</citation>
    <PMID>10666353</PMID>
  </reference>
  <reference>
    <citation>Orlova IA, Nuraliev EY, Yarovaya EB, Ageev FT. Prognostic value of changes in arterial stiffness in men with coronary artery disease. Vasc Health Risk Manag. 2010 Nov 4;6:1015-21. doi: 10.2147/VHRM.S13591.</citation>
    <PMID>21127698</PMID>
  </reference>
  <reference>
    <citation>Li Z, Iwai M, Wu L, Liu HW, Chen R, Jinno T, Suzuki J, Tsuda M, Gao XY, Okumura M, Cui TX, Horiuchi M. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension. 2004 Nov;44(5):758-63. Epub 2004 Sep 27.</citation>
    <PMID>15452025</PMID>
  </reference>
  <reference>
    <citation>Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging. 2010 Aug;26(6):631-40. doi: 10.1007/s10554-010-9616-1. Epub 2010 Mar 26.</citation>
    <PMID>20339920</PMID>
  </reference>
  <reference>
    <citation>Lunder M, Janić M, Savić V, Janež A, Kanc K, Šabovič M. Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2017 May;127:181-186. doi: 10.1016/j.diabres.2017.03.019. Epub 2017 Mar 22.</citation>
    <PMID>28384560</PMID>
  </reference>
  <reference>
    <citation>Lunder M, Janić M, Jug B, Sabovič M. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. Eur J Intern Med. 2012 Apr;23(3):261-6. doi: 10.1016/j.ejim.2011.11.011. Epub 2011 Dec 12.</citation>
    <PMID>22385885</PMID>
  </reference>
  <reference>
    <citation>Boncelj Svetek M, Eržen B, Kanc K, Šabovič M. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan. J Diabetes Complications. 2017 Mar;31(3):544-550. doi: 10.1016/j.jdiacomp.2016.12.002. Epub 2016 Dec 16.</citation>
    <PMID>28012835</PMID>
  </reference>
  <reference>
    <citation>Janić M, Lunder M, Cerkovnik P, Prosenc Zmrzljak U, Novaković S, Šabovič M. Low-Dose Fluvastatin and Valsartan Rejuvenate the Arterial Wall Through Telomerase Activity Increase in Middle-Aged Men. Rejuvenation Res. 2016 Apr;19(2):115-9. doi: 10.1089/rej.2015.1722. Epub 2016 Jan 22.</citation>
    <PMID>26214555</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Martina Turk Veselič</investigator_full_name>
    <investigator_title>Principal Investigator, M.D.</investigator_title>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>flow mediated dilatation</keyword>
  <keyword>fluvastatin</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

